EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Abeona Therapeutics's enterprise value is $280.01 Mil.
Abeona Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Abeona Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Abeona Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Abeona Therapeutics was 809.34. The lowest was -10.70. And the median was 44.32.
ABEO's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.34 * Ranked among companies with meaningful EV-to-Revenue only.
The historical data trend for Abeona Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Abeona Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Abeona Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's EV-to-Revenue falls into.
Abeona Therapeutics's current Enterprise Value is $280.01 Mil.
Abeona Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics's share price for today is $6.73.
Abeona Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Abeona Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABEO has been successfully added to your 